Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First in Human Phase 1 / 2 Multi-center Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of CTx001 Administered Via a Single Subretinal Injection in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

NCT07392255 is registered in ClinicalTrials.gov with Complement Therapeutics as lead sponsor.

NCT NCT07392255
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07392255 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First in Human Phase 1 / 2 Multi-center Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of CTx001 Administered Via a Single Subretinal Injection in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
Lead sponsor
Complement Therapeutics
Phase
Phase 1/2
Overall status
Recruiting
Start date
December 30, 2025
Completion date
June 30, 2032
Enrollment
75 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

geographic atrophy secondary to age-related macular degeneration